华润三九

000999.SZ

Wind Industry: 医疗保健 > 医药生物 > 制药 > 中药

公司主要从事医药产品的研发、生产、销售及相关健康服务，主营核心业务定位于CHC健康消费品和Rx处方药，产品覆盖领域广，并持续丰富产品线和品种。CHC健康消费品业务覆盖了感冒、皮肤、胃肠、止咳、骨科、儿科、膳食营养补充剂等品类，其核心产品占据了较高的市场份额。处方药业务覆盖了抗肿瘤、心脑血管、消化系统、骨科、儿科、抗感染等治疗领域，拥有参附注射液、示踪用盐酸米托蒽醌注射液、华蟾素片剂及注射剂、益血生胶囊、瘀血痹片、尪痹胶囊、注射用头孢比罗酯钠等多个处方药品种，在医疗端享有较高声誉。在产业链事业群领域，公司及旗下昆药集团相互赋能，协同发展，在三七产业发展和“777”及“昆中药1381”品牌打造上持续发力，推动昆药集团成为银发经济健康第一股。公司具有较强的品牌运作能力，多次上榜WPP年度最具价值中国品牌百强榜单。公司采取“1+N”品牌策略，以“999”为主品牌，在消费者和医药行业中均享有较高的认可度，多次被评为“中国最高认知率商标”“中国最有价值品牌”。公司陆续拓展“天和”“顺峰”“澳诺”“康妇特”“777”“昆中药1381”等深受消费者认可的药品品牌，并将其分别打造为骨科贴膏、皮肤用药、儿童健康、妇科用药、慢病管理、精品国药等领域的专业品牌，为长期的业务发展奠定了坚实的基础。

ESG Score Industry Ranking:
8 / 282 (制药)

ESG Rating Distribution(制药)

0.35%

AAA

2.84%

17.73%

20.21%

BBB

30.14%

24.11%

0.35%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.03Updated on 2026-10-29

08.0310

Management & Practices Score：5.03Updated on 2026-10-12

05.037

Controversies Score：3.00Updated on 2026-10-29

03.003

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	7.66	3.56	22.85%
Social	7.39	3.72	49.76%
Governance	6.42	5.34	27.39%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(282 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	600535.SH	天士力	AAA	8.94	3.00	5.94	9.07	8.63	7.75
2	301130.SZ	西点药业	AA	8.39	3.00	5.39	7.28	7.78	7.92
3	3320.HK	华润医药	AA	8.31	3.00	5.31	7.23	7.73	7.62
4	600380.SH	健康元	AA	8.22	3.00	5.22	5.64	8.16	7.66
5	603896.SH	寿仙谷	AA	8.18	3.00	5.18	6.54	7.51	7.92
6	600329.SH	达仁堂	AA	8.15	3.00	5.15	6.24	7.44	8.16
7	601607.SH	上海医药	AA	8.07	3.00	5.07	7.19	7.17	7.40
8	000999.SZ	华润三九	AA	8.03	3.00	5.03	7.66	7.39	6.42
9	301281.SZ	科源制药	A	7.99	2.99	4.99	5.58	7.51	7.72
10	000513.SZ	丽珠集团	AA	7.94	2.99	4.94	5.51	7.94	6.76